QPS
John Kolman is the current Vice President and Global Head of Translational Medicine at QPS. John has held this position for 7 years and 9 months. Prior to this, they worked at QPS Holdings, LLC for 3 years as an Executive Director and Head of Translational Medicine. In this role, they were responsible for the business, technical, and development leadership of a top tier bio-analytical Contract Research Organization. John's additional responsibilities included overseeing two QPS sister laboratories in the EU and Asia, emphasizing process and system harmonization, and identifying and onboarding global clients with multi-site clinical trials.
Kolman is an expert in biomarker research & development and innovative life science. John uses their broad expertise in all areas pertinent to translational and individualized medicine to help clients accelerate the development of personalized drug and genetic therapies. Working with QPS’ Strategic Leadership Team, they assist clients in quickly moving drug candidates from pre-clinical through late stage development using diagnostic tests that allows the selection of appropriate and optimal drug therapies based on a patient's DNA, RNA, and/or protein pathophysiology.
This person is not in any offices
QPS
QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities. We are passionate about our work, creating value for patients and customers while generating opportunities for employees to thrive.